Publications by authors named "Subbareddy Gunneri"

Claim this Profile
I
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study.
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla

IJID Reg· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial.
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Rammohan Reddy Mogulla, Vijay Yerroju

Lancet Reg Health Southeast Asia· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEV concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study.
Subhash Thuluva, Ramesh V Matur, SubbaReddy Gunneri, Rammohanreddy Mogulla, Chirag Dhar

IJID Reg· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study.
Subhash Thuluva, Ramesh V Matur, Subbareddy Gunneri, Rammohan Reddy Mogulla, Kamal Thammireddy

Front Immunol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Ramesh V Matur, Subhash Thuluva, Subbareddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla

Vaccine· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Mogulla

Hum Vaccin Immunother· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.
Subhash Thuluva, SubbaReddy Gunneri, Kishore Turaga, Rammohan Reddy Mogulla, Vijay Yerroju

Contemp Clin Trials Commun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla

Vaccine· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis